Navigation Links
Cato Research Presents at Korea-Maryland, USA BIO EXPO, Drug Development Process and Regulatory Approaches
Date:11/7/2013

Durham, NC (PRWEB) November 07, 2013

Cato Research clinical research physician and managing director for Cato Research’s Washington office, Jack Snyder, M.D., Ph.D., R.A.C., D.A.B.T., C.P.I., and Cato Research regulatory expert Elinore M. Mercer, Ph.D., R.A.C., will present in Rockville, Maryland, at the Korea-Maryland, United States of America Bio Expo, Drug Development Process and Regulatory Approaches.    

Dr. Jack Snyder will present the following sessions:

Session 1: “IND Process – Nonclinical”
1. Pharmacology and Toxicity Study Design and Guidance
2. Case Studies in Pharmacology and Toxicology

Session 2: “CMC Process”
1. USP Identification Standards
2. Chemistry Section
3. Specifications for CMC / CMC
4. FDA Pertinent Guidance

Session 3: “Pharmacometrics and Clinical Trials Design”
1. Data Analysis, Pharmacometrics and Clinical Trial Design Statistical Methodology for Design
2. and Evaluation of Clinical Trials
3. Use of SAS, Population Modeling, PK/PD Modeling
4. Case Studies and Pertinent FDA Guidances

Dr. Elinore Mercer will copresent Friday, November 8th on the following:

Session 7: "Innovative Strategies for New Drug Development"
1. Current Initiatives for Repurposing Pharmaceuticals and New Development
2. Biosimilar Strategies and Current Guideline Discussion
3. Biosimilar/Follow-on Biologics; Pertinent FDA Guidance

Dr. Snyder serves as a Clinical Research Physician and managing director for Cato Research’s Washington office as well as a Medical Analyst for Cato BioVentures. Dr. Snyder is a pharmacologist-toxicologist-pathologist with more than 25 years’ experience in academia, government, and industry. Dr. Snyder has experience in diverse areas of business, including project management, policy development, strategic planning, regulatory and safety compliance, intellectual property, and quality control and improvement. He has conducted basic and clinical research, practiced clinical and laboratory medicine, inspected a variety of research and clinical laboratories, and edited or authored more than 120 publications.

Dr. Mercer is a Regulatory Scientist at Cato Research where she crafts regulatory strategies for biologics and drugs based on the ever-changing regulatory environment. Prior to joining Cato Research, Dr. Mercer did her Ph.D. training at the University of California, San Diego, and her post-doctoral work at the Genomics Institute of the Novartis Research Foundation. She also had stints at biotechs Genoptix and Kalypsys, and acts as a scientific analyst for the ventures arm of Cato Research, Cato BioVentures.

For more information about this event, please visit:
http://www.cato.com/events.shtml

About Cato Research
Founded in 1988 by Dr. Allen Cato and Lynda Sutton and headquartered near Research Triangle Park, North Carolina, Cato Research is a full-service, global contract research and development organization providing strategic and tactical support for clients in the pharmaceutical, biotechnology, and medical device industries. Services range from design and management of preclinical and clinical studies to submission of regulatory documents required for marketing approval. With a staff of approximately 300 and offices located in the United States, Europe, Canada, Israel, and South Africa, the Cato Research team consistently demonstrates an unsurpassed level of responsiveness, flexibility, attention to detail, and passion for bringing their clients’ products to market with speed and cost-effectiveness.

For more information, please contact:

Cato Research
Phone: 919-361-2286
http://www.cato.com
# # #

Read the full story at http://www.prweb.com/releases/2013/11/prweb11309105.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Diabetic flies can speed up disease-fighting research
2. Regado Biosciences, Inc. Appoints World-Renowned Leader in Cardiovascular Research and Former Global Head of Cardiovascular Diseases for Merck & Co., to Board of Directors
3. Bend Research to Highlight Latest Drug Formulation Technologies
4. Shocking News & Research: Boston Scientific, Yingli Green Energy Hold, QUALCOMM, PulteGroup, Regions Financial
5. Clinical Research Site-Expert Johan Karlberg to Lead ACRES Global Network Development
6. Global In Vitro Fertilization Market 2012-2016: Industry Analysis, Size, Share, Growth, Trends and Forecast New Research Report Available at MarketResearchReports.biz
7. NPL leads research project to help deliver 10x faster computer processing speeds
8. BCC Research Publishes a New Report On Global Markets for Flow Cytometry
9. York researchers discover important mechanism behind nanoparticle reactivity
10. First Annual Michael SanInocencio Lennox-Gastaut Syndrome Research Award Presented at Annual Meeting of the Child Neurology Society
11. Hun School Bio Students Conduct Original Molecular Research in Conjunction with Rutgers University
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... According to a new ... Service), Type (Safety, Efficacy, Validation), Disease Indication (Cancer, ... Development, Disease-Risk) - Global Forecast to 2021" published ... USD 53.34 Billion by 2021 from USD 27.95 ... 13.8% during the forecast period (2016-2021). ...
(Date:2/17/2017)... Feb. 17, 2017  Protagonist Therapeutics, Inc. (NASDAQ: ... its oral peptide drug candidates, PTG-100 and PTG-200, ... European Crohn,s and Colitis Organization (ECCO).  The ECCO ... Spain from February 15 – 18, ... data on Protagonist drug candidates PTG-100 and PTG-200. ...
(Date:2/16/2017)... Calif. and GREENWICH, Conn. ... a private investment firm focused on venture growth ... the promotion of Josh Richardson , M.D. ... on investments in biotechnology companies.  He is a ... played important roles in Longitude,s investments in Aimmune ...
(Date:2/16/2017)... , Feb. 16, 2017   Capricor Therapeutics, ... clinical-stage biotechnology company developing first-in-class biological therapies for ... it has elected to terminate its license agreement ... receptor agonists, including Cenderitide. "Our decision ... as we prioritize our efforts to advance our ...
Breaking Biology Technology:
(Date:1/23/2017)... DENVER , Jan. 23, 2017  The latest ... biometric smartphone prices have dropped dramatically. The quarterly average ... Q1 2013 to $276 in Q4 2016.  There are ... average price of $116, up from just 28 a ... According to Maxine Most , Acuity ...
(Date:1/19/2017)... Oregon and PUNE, India , January 19, 2017 ... Research, titled, "Global Biometric Sensor Market, Opportunities and Forecast, 2014 - 2022," ... growing at a CAGR of 9.6% from 2016 to 2022. In 2015, ... owing to high-level security for both public and private sectors. ... ...
(Date:1/18/2017)... Jan. 18, 2017  In vitro diagnostic (IVD) companies ... and acquisitions (M&A), and Kalorama Information expects that trend ... have been shifting. Generally, uncertainty in reimbursement and healthcare ... U.S. has changed the acquisitions landscape. Instead of looking ... companies buying partners outside of their home country and ...
Breaking Biology News(10 mins):